AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q85108

Application No.: 10/517,422

**AMENDMENTS TO THE CLAIMS** 

This listing of claims will replace all prior versions and listings of claims in the

application:

LISTING OF CLAIMS:

1. (currently amended): A method for classifying and counting leukocytes, which

comprises:

(1) a step of staining cells in a sample obtained from a hematological sample by

treatment with a hemolytic agent, with a fluorescent dye which can make a difference in the

fluorescence intensity at least among mature leukocytes, leukocytes with abnormal DNA amount

and immature leukocytes;

(2) a step of introducing the sample containing the stained cells into a flow cytometer to

measure first scattered light, second scattered light different from the first scattered light and

fluorescence of the respective cells;

(3) a step of classifying a first group and a second group utilizing a difference in the

intensity of a obtaining scattered light peak intensities and a difference in the scattered light

width, the first group including leukocytes and second group including coincidence cells and

platelet clumps widths of the respective cells based on the measured first scattered light,

obtaining scattered light intensities of the respective cells based on the measured second

scattered light, and obtaining fluorescence intensities of the respective cells based on the

measured fluorescence light;

(4) a step of classifying the cells into a first group and a second group based on the

scattered light peak intensities and the scattered light widths, the first group including leukocytes

and the second group including coincidence cells and platelet clumps;

2

Application No.: 10/517,422

Attorney Docket No.: Q85108

(5) a step of classifying and counting the leukocytes included in the first group into mature leukocytes, leukocytes with abnormal DNA amount and immature leukocytes, utilizing a difference in based on the scattered light intensity intensities and a difference in the fluorescence

intensity intensities of the leukocytes classified in the step (3) included in the first group; and

(6) a step of counting the classified mature leukocytes, the classified leukocytes with

abnormal DNA amount and the classified immature leukocytes.

2. (original): The method according to claim 1, which further comprises a step of

calculating a ratio of mature leukocytes or immature leukocytes relative to leukocytes with

abnormal DNA amount from a number of leukocytes with abnormal DNA amount and a number

of mature leukocytes or immature leukocytes.

3. (previously presented): The method according to claim 1, which further comprises a

step of calculating a ratio of immature leukocytes relative to mature leukocytes from a number of

mature leukocytes and a number of immature leukocytes.

4 - 5. (canceled).

6. (previously presented): The method according to any one of claims 1 to 5claim 1,

wherein the fluorescent dye is selected from the group consisting of a compound represented by

the formula (I):

3

Application No.: 10/517,422

Attorney Docket No.: Q85108

(wherein R<sup>11</sup> is a hydrogen atom or a lower alkyl group; R<sup>21</sup> and R<sup>31</sup> each is a hydrogen atom, a lower alkyl group or a lower alkoxy group; R<sup>41</sup> is a hydrogen atom, an acyl group or a lower alkyl group; R<sup>51</sup> is a hydrogen atom or a lower alkyl group which may be substituted; Z is sulfur atom, oxygen atom, or carbon atom which is substituted by a lower alkyl group; n<sup>1</sup> is 1 or 2; and X<sup>1-</sup> is an anion), ethidium bromide, propidium iodide, ethidium-acridine heterodimer, ethidium azide, ethidium homodimer-1, ethidium homodimer-2, ethidium monoazide, TOTO-1, TOTO-3, and TO-PRO-3.

- 7. (previously presented): The method according to claim 1, wherein the hemolytic agent comprises the following components:
  - (1) a polyoxyethylene nonionic surfactant;
- (2) a solubilizing agent to give damage to cell membrane of blood corpuscles and reduce their size;
  - (3) an amino acid; and
- (4) a buffer by which pH and osmotic pressure of the liquid are adjusted to 5.0 9.0 and 150-600 mOsm/kg, respectively.

Application No.: 10/517,422

8. (previously presented): The method according to claim 7, wherein the polyoxyethylene nonionic surfactant comprises a compound represented by the following formula (II):

$$R^{III}\text{-}R^{2II}\text{-}(CH_2CH_2O)n_{II}\text{-}H \tag{II}$$

(wherein R<sup>1II</sup> represents a C<sub>9-25</sub> alkyl, alkenyl or alkynyl group; R<sup>2II</sup> represents -O-,

Attorney Docket No.: Q85108

or -COO-; and  $n_{II}$  is 10-40).

9. (previously presented): The method according to claim 7, wherein the solubilizing agent is a compound selected from the group consisting of

a sarcosine derivative of the formula (III):

$$\begin{array}{c|c} & \text{O} & \text{CH}_3 \\ \parallel & \mid & \\ \text{R}^{1 \parallel \text{I}} & \text{C} & \text{N} & \text{(III)} \end{array}$$

(wherein R<sup>IIII</sup> is a C<sub>10-22</sub> alkyl group; and n<sup>III</sup> is 1-5)

or salts thereof;

a cholic acid derivative of the formula (IV):

$$\begin{array}{c|c} & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & \\ & & \\ & \\ & & \\$$

(wherein R<sup>1IV</sup> is a hydrogen atom or a hydroxy group);

and

a methylglucanamide of the formula (V):

(wherein n<sup>V</sup> is 5-7).

10. (previously presented): The method according to claim 1, wherein scattered light to be measured is selected from forward low angle scattered light, forward high angle scattered light and side scattered light.

Application No.: 10/517,422

11. (withdrawn): A system for classifying and counting leukocytes which comprises:

Attorney Docket No.: Q85108

a flow cytometer comprising an orifice portion in which a sample for measurement passes through, a light source which irradiates light to the orifice portion, a first light receiving portion which receives scattered light emitted from the orifice portion and a second light receiving portion which receives fluorescence emitted from the orifice portion, said sample for measurement being prepared by a step of mixing a hematological sample with a hemolytic agent and a step of staining cells in the resulting mixture with a fluorescent dye which can make a difference in the fluorescence intensity at least among mature leukocytes, leukocytes with abnormal DNA amount and immature leukocytes; and

an analyzing part in which the sample for measurement is analyzed by a step of classifying a first group and a second group utilizing a difference in the intensity of a scattered light peak and a difference in the scattered light width, the first group including leukocytes and the second group including coincidence cells and platelet clumps and a step of classifying and counting mature leukocytes, leukocytes with abnormal DNA amount and immature leukocytes, utilizing a difference in the intensity and a difference in the fluorescence intensity of leukocytes classified.

12. (new): The method according to claim 1, wherein the classifying step (5) is performed so as to classify the classified mature leukocytes into at least three groups based on the scattered light intensities.

Application No.: 10/517,422

Attorney Docket No.: Q85108

13. (new): The method according to claim 1, wherein the classifying step (5) is performed so as to classify the classified immature leukocytes into at least two groups based on the scattered light intensities.